Last reviewed · How we verify

CsA+Herombopag — Competitive Intelligence Brief

CsA+Herombopag (CsA+Herombopag) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist. Area: Hematology / Immunology.

marketed Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist Calcineurin (CsA); thrombopoietin receptor / MPL (herombopag) Hematology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CsA+Herombopag (CsA+Herombopag) — Peking Union Medical College Hospital. CsA (cyclosporine A) suppresses T-cell activation while herombopag stimulates thrombopoietin receptors to increase platelet production, together addressing immune-mediated thrombocytopenia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CsA+Herombopag TARGET CsA+Herombopag Peking Union Medical College Hospital marketed Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist Calcineurin (CsA); thrombopoietin receptor / MPL (herombopag)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist class)

  1. Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CsA+Herombopag — Competitive Intelligence Brief. https://druglandscape.com/ci/csa-herombopag. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: